licensing

Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

AETOSWire July 18, 2022

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement...

Hikma expands licensing agreement with Celltrion for Remsima® subcutaneous formulation in MENA

Hikma expands licensing agreement with Celltrion for Remsima® subcutaneous formulation in MENA

Hikma expands licensing agreement with Celltrion for Remsima® subcutaneous formulation in MENA

AETOSWire February 7, 2022

London, United Kingdom– (AETOSWire) Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement with...